<DOC>
	<DOCNO>NCT00001302</DOCNO>
	<brief_summary>The clinical study entitle `` A Phase I Study Infusional Chemotherapy P-glycoprotein Antagonist PSC 833 '' seek determine maximum tolerate dose propose P-glycoprotein antagonist , PSC 833 . PSC 833 cyclosporine analogue purportedly non-nephrotoxic non-immunosuppressive . It show in-vitro study enhance chemosensitivity well cyclosporine far well increase intracellular drug accumulation concentration verapamil clinically achievable . The purpose study define maximum tolerate dose combination vinblastine , determine drug affect pharmacokinetics vinblastine . PSC 833 likely reduce clearance vinblastine , report parent compound , cyclosporine . This effect increase area curve ( AUC ) vinblastine , may increase toxicity , require escalation scheme PSC 833 conservative one . Initially , 120 hour infusion vinblastine give alone . Then 8 day PSC 833 follow allow monitoring adverse effect PSC 833 alone . This first cycle vinblastine give absence PSC 833 ; second subsequent cycle agent combine . Escalation PSC 833 continue target concentration reach , maximum tolerate dose reach . Clinical response monitor order provide best possible medical care patient .</brief_summary>
	<brief_title>A Phase I Study Infusional Chemotherapy With P-Glycoprotein Antagonist PSC 833</brief_title>
	<detailed_description>The clinical study entitle `` A Phase I Study Infusional Chemotherapy P-glycoprotein Antagonist PSC 833 '' seek determine maximum tolerate dose propose P-glycoprotein antagonist , PSC 833 . PSC 833 cyclosporine analogue purportedly non-nephrotoxic non-immunosuppressive . It show vitro study enhance chemosensitivity well cyclosporine far well increase intracellular drug accumulation concentration verapamil clinically achievable . The purpose study define maximum tolerate dose combination vinblastine , determine drug affect pharmacokinetics vinblastine . PSC 833 likely reduce clearance vinblastine , report parent compound , cyclosporine . This effect increase area curve ( AUC ) vinblastine , may increase toxicity , require escalation scheme PSC 833 conservative one . Initially , 120 hour infusion vinblastine give alone . Then 8 day PSC 833 follow allow monitoring adverse effect PSC 833 alone . This first cycle vinblastine give absence PSC 833 ; second subsequent cycle agent combine . Escalation PSC 833 continue target concentration reach , maximum tolerate dose reach . Clinical response monitor order provide best possible medical care patient .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Biopsy proven metastatic cancer , good therapy exists . All patient eligible . Enrollment patient kidney , breast , ovarian cancer , lymphomas encourage . A life expectancy least 16 week , performance status ( Karnofsky scale ) 70 % great . Patients without rapidly grow disease . Any prior therapy except previous bone marrow transplantation . WBC great 3,000/mm3 ACG great 1,000/mm3 ; platelet great 100,000/mm3 . Creatinine Clearance great 50 ml/min ; bilirubin less 1.5 mg/dl ; SGOT le 70u/L ; SGPT le 80u/L . A sign informed consent geographic accessibility patient return follow treatment . No history brain metastasis . Not currently receive treatment follow agent agent know significantly interact cyclosporine , treatment discontinue , change another therapeutically equivalent allowable drug : acetazolamide , barbiturate , corticosteroid , diltiazem , erythromycin , fluconazole , ketoconazole , nicardipine , phenothiazine , phenytoin , rifampin , sulfonamide , trimethoprim , verapamil , tamoxifen , progesterone , quinine , quinidine , amiodarone . No symptomatic peripheral neuropathy ( grade 2 great arise prior vinca alkaloid therapy ) . No positive serology HIV . No ongoing pregnancy unwillingness practice adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>Vinblastine</keyword>
	<keyword>Multidrug Resistance</keyword>
	<keyword>Resistance Reversal</keyword>
	<keyword>Pgp Blocker</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Drug Interactions</keyword>
</DOC>